236P - Possible Use of Urinary Prostate Proteins Glycosylation Profile As a Diagnostic Biomarker for Prostate Cancer

Abstract

ABSTRACT Aim: Serum Prostate Specific Antigen (sPSA) is widely used for screening and early diagnosis of prostate cancer (PCa). This analysis is associated with considerable sensitivity and specificity problems, especially in the diagnostic grey zone (sPSA between 4 and 10 ng/mL). Other biomarkers have emerged but only few have shown clinical significance. Because of aberrant glycosylation changes in tumorogenesis, we explored the use of urinary prostate proteins and its glycosylation profile as a new biomarker for PCa. Methods: We determined sPSA and urinary biomarkers in healthy volunteers (HV; n = 54), patients with benign prostate hyperplasia (BPH; n = 99) and PCa patients (n = 74). Urinary prostate protein N-glycans were determined by fluorophore-assisted carbohydrate electrophoresis. Results: N-glycan profile analyses have pointed out differences between the subject groups: a decrease in overall fucosylation was noticed in PCa patients compared to patients with BPH and HV (p = 0.001 and p Multivariate logistic regression Variables OR (95% CI) P-value Age 0.99 (0.94–1.04) n.s. SPSA 1.19 (1.09–1.30) 0.0001 UGM 1.50 (1.26–1.79) Conclusions: Our urinary marker was able to differentiate between BPH and PCa. These changes in N-glycosylation could lead to the discovery of a new biomarker for PCa, which seems particularly useful in the diagnostic gray zone of sPSA concentration between 4 and 10 ng/mL. Disclosure: All authors have declared no conflicts of interest.